Zynex, Inc. (NASDAQ:ZYXI) CEO Thomas Sandgaard Sells 2,000 Shares

Zynex, Inc. (NASDAQ:ZYXI) CEO Thomas Sandgaard sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, November 4th. The stock was sold at an average price of $8.67, for a total value of $17,340.00. Following the completion of the sale, the chief executive officer now owns 14,619,350 shares of the company’s stock, valued at $126,749,764.50. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

Thomas Sandgaard also recently made the following trade(s):

• On Wednesday, November 6th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.82, for a total value of $17,640.00.
• On Friday, November 1st, Thomas Sandgaard sold 2,000 shares of Zynex stock. The stock was sold at an average price of $8.63, for a total transaction of $17,260.00.
• On Wednesday, October 30th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.92, for a total transaction of $17,840.00.

Zynex Stock Up 10.2 %

Shares of NASDAQ:ZYXI opened at $9.21 on Thursday. The company’s fifty day moving average is $8.14 and its 200-day moving average is $9.00. The company has a debt-to-equity ratio of 1.66, a quick ratio of 3.15 and a current ratio of 3.94. Zynex, Inc. has a 52 week low of $7.15 and a 52 week high of $13.77. The company has a market capitalization of $293.30 million, a PE ratio of 61.40 and a beta of 0.53.

Zynex (NASDAQ:ZYXI) last released its quarterly earnings results on Thursday, October 24th. The company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.01. The firm had revenue of $49.97 million for the quarter, compared to analyst estimates of $50.83 million. Zynex had a net margin of 2.49% and a return on equity of 13.05%. The company’s revenue for the quarter was up .1% compared to the same quarter last year. During the same period in the previous year, the business earned $0.10 earnings per share. Equities research analysts predict that Zynex, Inc. will post 0.2 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Zynex

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Gladius Capital Management LP boosted its stake in Zynex by 53.4% in the third quarter. Gladius Capital Management LP now owns 5,002 shares of the company’s stock worth $41,000 after purchasing an additional 1,742 shares in the last quarter. Investment Partners Asset Management Inc. acquired a new position in Zynex during the 3rd quarter worth about $96,000. Hsbc Holdings PLC bought a new stake in Zynex during the 2nd quarter worth about $113,000. Quest Partners LLC increased its position in Zynex by 646.7% in the 2nd quarter. Quest Partners LLC now owns 12,926 shares of the company’s stock valued at $120,000 after acquiring an additional 11,195 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System acquired a new stake in Zynex in the 1st quarter valued at about $137,000. 29.68% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently weighed in on ZYXI. HC Wainwright upped their target price on shares of Zynex from $16.00 to $17.00 and gave the company a “buy” rating in a research note on Friday, October 25th. Royal Bank of Canada lowered their price objective on Zynex from $12.00 to $11.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.